4.6 Article

Feasibility and validation of a computer-automated Columbia-Suicide severity rating scale using interactive voice response technology

期刊

JOURNAL OF PSYCHIATRIC RESEARCH
卷 44, 期 16, 页码 1224-1228

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jpsychires.2010.04.025

关键词

Suicide assessment; Interactive voice response (IVR); Patient Safety; Depression; Methodology

资金

  1. GlaxoSmithKline
  2. Pfizer
  3. Eli Lilly
  4. Eisai
  5. National Institutes of Health (NIMH, NIAAA)
  6. US Department of Agriculture
  7. AstraZeneca
  8. Forest
  9. Janssen
  10. Jazz
  11. Lilly
  12. National Institutes of Mental Health and Aging
  13. Novartis
  14. American Psychiatric Institute for Research Education
  15. Charles T. Engelhard Foundation

向作者/读者索取更多资源

Objective: To evaluate a computer-automated version of the Columbia-Suicide Severity Rating Scale (C-SSRS) using interactive voice response technology (eC-SSRS (TM)). The eC-SSRS assesses Lifetime ideations and behaviors at baseline and monitors suicidality prospectively thereafter. Ten control volunteers and ten psychiatric inpatients participated and were administered the C-SSRS at baseline and 4-8 days later by two experienced clinical trial raters. Study participants also completed the eC-SSRS using touch-tone telephones. Kappa measures of agreement compared inter-rater reliability of the C-SSRS administrations and the C-SSRS administrations with the eC-SSRS. Convergent validity with the Beck Scale for Suicide Ideation BSS and patient feedback forms were also evaluated. Twenty baseline and nineteen follow-up assessments were completed. In general, agreement between the eC-SSRS and each rater was comparable or superior to the agreement between both raters. Subject feedback and personal preferences varied across individuals, but were generally supportive of the feasibility and validity of the eC-SSRS. The reliability and validity of the C-SSRS and eC-SSRS for assessing suicidal ideation and behaviors were comparable in this first study comparing the methods. These data were obtained from relatively small patient samples recruited from a single investigational site over a relatively short follow-up period. They support the feasibility and validity of the eC-SSRS for prospective monitoring of suicidality for use in clinical trials or clinical care, but further research with larger samples, other patient populations, and longer follow-up periods is needed. (C) 2010 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据